Title:
SIRNA FOR INHIBITING COMPLEMENT FACTOR B EXPRESSION, PHARMACEUTICAL COMPOSITION AND CONJUGATE THEREOF, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/008114
Kind Code:
A1
Abstract:
The present invention relates to an siRNA capable of inhibiting the expression of a complement factor B (CFB) gene, an siRNA conjugate, a pharmaceutical composition comprising same, and a use thereof. Each nucleotide in the siRNA is independently a modified or unmodified nucleotide, and the siRNA contains a sense strand and an antisense strand. The siRNA as well as the pharmaceutical composition and the conjugate thereof can effectively treat and/or prevent diseases related to CFB gene overexpression.
More Like This:
| WO/1995/027054 | USE OF DNA OLIGOMERS FOR INHIBITION OF HIV BY DECREASING RIBOSOMAL FRAMESHIFTING |
| JPWO2003070932 | Polynucleotide for target gene |
| WO/2022/056269 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE |
Inventors:
WANG SHUCHENG (CN)
HUANG HE (CN)
LIU WEI (CN)
WANG YAN (CN)
LIN GUOLIANG (CN)
CHAN YUNXIA (CN)
GENG YUXIAN (CN)
WANG XIAOJUN (CN)
RONG MEI (CN)
HUANG HE (CN)
LIU WEI (CN)
WANG YAN (CN)
LIN GUOLIANG (CN)
CHAN YUNXIA (CN)
GENG YUXIAN (CN)
WANG XIAOJUN (CN)
RONG MEI (CN)
Application Number:
PCT/CN2023/105855
Publication Date:
January 11, 2024
Filing Date:
July 05, 2023
Export Citation:
Assignee:
BEIJING WINSUNNY PHARMACEUTICAL CO LTD (CN)
International Classes:
C12N15/113; A61K31/713; A61P13/12; A61P27/02; A61P35/00
Domestic Patent References:
| WO2021222549A1 | 2021-11-04 | |||
| WO2018117253A1 | 2018-06-28 |
Foreign References:
| CN116769780A | 2023-09-19 | |||
| CN105814205A | 2016-07-27 |
Attorney, Agent or Firm:
PEKSUNG INTELLECTUAL PROPERTY LTD. (CN)
Download PDF: